ClinicalTrials.gg
Not yet recruitingNCT07861776isHLH-IVD/IVIgUpdated Oct 6, 2026

Efficacy of Short Course of Intravenous Dexamethasone and Intravenous Immunoglobulin Therapy in Infection-Related Secondary Hemophagocytic Lymphohistiocytosis (isHLH)

A Phase 3 interventional study of Intravenous Immunoglobulin (IVIg) therapy and Intravenous Dexamethasone (IVD) therapy in Hemophagocytic Lymphohistiocytosis (HLH) and Secondary Hemophagocytic Lymphohistiocytosis, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Phase 3, Interventional, and Treatment

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Rationale/Gaps in Existing Knowledge: Therapy of Infection-associated Secondary Hemophagocytic lymphohistiocytosis (sHLH) in adult lacks evidence from randomized trial guiding first-line immunomodulation and current therapeutic practice primarily extrapolated from decades old pediatric HLH protocols and retrospective studies. In presence of infection very expensive therapy with intravenous Immunoglobulin (IVIG) is preferred over Dexamethasone, however the comparative efficacy of IVIG and Dexamethasone alone remains undefined, especially in resource-constraints settings. (ii) Novelty: This will be among the first randomized controlled trials in adults with infection-associated sHLH, directly comparing efficacy of IVIG with Dexamethasone. The study uniquely integrates clinical outcomes with economic feasibility in a low-middle income setting. (iii) Objectives: Primary objectives will be to compare the efficacy of intravenous (IV) Dexamethasone and IVIG in achieving clinical remission and recovery of HLH-associated cytokines (IL-1, IL-6, TNF-α, IFN-γ, GM-CSF) and Ferritin level. Secondary objectives include assessment of hematologic recovery, adverse events, and short-term mortality. (iv)Method: In this Randomized controlled open-label, non-inferiority clinical trial participants with sHLH, will be allocated (1:1) to receive either short-course of IV Dexamethasone or IVIG along with infection-directed standard care and will be followed-up for 4 weeks to evaluate predefined clinical outcome and laboratory parameters. (v) Expected Outcome: The study aims to establish whether IV Dexamethasone is non-inferior to IVIG for achieving clinical remission, recovery of HLH-associated cytokines level and reduction of short-term mortality. Results are expected to reform evidence-based, cost-effective therapeutic strategies for infection-associated sHLH and improve access to care in resource-constraint healthcare systems.

02

Conditions studied

  • Hemophagocytic Lymphohistiocytosis (HLH)
  • Secondary Hemophagocytic Lymphohistiocytosis

Keywords

  • Hemophagocytic lymphohistiocytosis (HLH)
  • Dexamethasone
  • Intravenous Immunoglobulin (IVIg)
  • Infection associated secondary HLH (isHLH)
03

In context

Lymphohistiocytosis, Hemophagocytic

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

This study's planned enrollment of 116 is above the median of 30 across 75 interventional studies indexed under Lymphohistiocytosis, Hemophagocytic.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Lead sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 298 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Gender: Male/female
  • h-Score probability ≥ 80%
  • Known microbiological etiology
  • Mild HLH not responding to infection specific targeted antimicrobial therapy (> 72 hours)
  • Mild HLH developing new organ dysfunction
  • Moderate to severe HLH with life threatening organ dysfunction

Exclusion criteria

Exclusion Criteria:

  • Primary (familial) HLH
  • associated HLH
  • HLH associated with disease
  • EBV associated HLH
  • Pregnancy
  • Receiving immune modulator therapy within 2 moths
  • Participants with
  • Consent not given
  • Known to IVIG or Dexamethasone
  • Chronic liver disease
  • Chronic kidney disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Active comparator
    IVIg

    Will receive intravenous Immunoglobulin (IVIg) therapy

    Drug: Intravenous Immunoglobulin (IVIg) therapy · Drug: Targeted antimicrobial therapy & standard care

  • Experimental
    IVD

    Will receive intravenous Dexamethasone (IVD)

    Drug: Intravenous Dexamethasone (IVD) therapy · Drug: Targeted antimicrobial therapy & standard care

Interventions

  • DrugImmunoglobulins, IntravenousStudies of Immunoglobulins, IntravenousImmunoglobulins, Intravenous pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Injection IVIg (400 mg/kg Body weight) over an hour IV infusion X 5 days (total cumulative dose 2g/kg).

  • DrugIntravenous Dexamethasone (IVD) therapy

    Injection Dexamethasone (10mg/m2) in 100 ml 0.9% normal saline (NS) over half an hour IV infusion X 3 days

  • DrugTargeted antimicrobial therapy & standard care

    Infection specific targeted antimicrobial therapy along with standard medical care

06

What researchers measure

Primary outcomes

  1. Clinical remission

    Number of participants become persistently asymptomatic without fever for ≥72 hours with h-Score probability \<80% and without any HLH-related new organ dysfunction at 1 week and 4 weeks of the IVIG/IVD intervention

    Time frame: 4 weeks

  2. The recovery of HLH-associated cytokines

    Number of participants having reduction of HLH-associated cytokines (IL-1, IL-6, TNF-α, IFN-γ, GM-CSF) and Ferritin level from the pre-intervention baseline at 1 week and 4 weeks of the IVIG/IVD intervention

    Time frame: 4 weeks

Secondary outcomes

  1. Recovery of the hematological parameters

    Number of participants with recovery or normalization of the hematological parameters (hemoglobin, total leukocyte count, and platelet count)

    Time frame: 4 weeks

  2. Adverse events/ adverse drug reactions

    Number of incidence of any adverse events and adverse drug reactions

    Time frame: 4 weeks

  3. Duration of hospital stay

    Number of days of hospital admission

    Time frame: 4 weeks

  4. Incidence of relapse of HLH: Recurrence of HLH after achieving clinical remission

    Number of participants having recurrence of HLH after achieving clinical remission

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — All the reasonable data requests should be submitted to the principal investigator (DPD) for consideration.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Sep 2029, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 6, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861776
Collaborators
Indian Council of Medical Research
Responsible party
Deba Prasad Dhibar (Principal investigator, Post Graduate Institute of Medical Education and Research, Chandigarh) — Principal investigator
First posted
Oct 6, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Deba Prasad Dhibar, MD
Contact
drdeba_prasad@yahoo.co.in
+911722756670
Deba Prasad Dhibar, MD
principal investigator · Post Graduate Institute of Medical Education and Research, Chandigarh, India

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion